# Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal

> **NCT05050825** · NA · UNKNOWN · sponsor: **Foundation for Innovative New Diagnostics, Switzerland** · enrollment: 470 (estimated)

## Conditions studied

- Malaria
- Dengue
- Influenza -Like Illness
- Diarrhea
- Pneumonia
- Acute Febrile Illness

## Interventions

- **OTHER:** Patient clinical management based on the CDSA strategy

## Key facts

- **NCT ID:** NCT05050825
- **Lead sponsor:** Foundation for Innovative New Diagnostics, Switzerland
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-03
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-12-15
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2021-10-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050825, "Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05050825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*